clofarabine has been researched along with pyrazines in 5 studies
| Studies (clofarabine) | Trials (clofarabine) | Recent Studies (post-2010) (clofarabine) | Studies (pyrazines) | Trials (pyrazines) | Recent Studies (post-2010) (pyrazines) |
|---|---|---|---|---|---|
| 424 | 101 | 280 | 12,165 | 1,373 | 5,747 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Giles, FJ | 1 |
| Cheson, BD | 1 |
| Bashir, Q; Bayraktar, UD; Champlin, RE; Ciurea, SO; Qazilbash, M | 1 |
| Imai, K | 1 |
| Abbenante, MC; Derenzini, E; Ferrari, A; Ghelli Luserna Di Rorà, A; Guadagnuolo, V; Iacobucci, I; Imbrogno, E; Martinelli, G; Paolini, S; Papayannidis, C; Parisi, S; Robustelli, V; Sartor, C | 1 |
4 review(s) available for clofarabine and pyrazines
| Article | Year |
|---|---|
New drugs in acute myeloid leukemia.
Topics: Acute Disease; Adenine Nucleotides; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Arabinonucleosides; Azacitidine; Bevacizumab; Boronic Acids; Bortezomib; Clofarabine; Cytosine; Decitabine; Dioxolanes; Humans; Indoles; Leukemia, Myeloid; Phthalazines; Pyrazines; Pyridines; Pyrroles; Thionucleotides | 2002 |
Hematologic malignancies: new developments and future treatments.
Topics: Adenine Nucleotides; Alemtuzumab; Alkaloids; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Agents; Apoptosis; Arabinonucleosides; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Cell Cycle; Cell Survival; Clofarabine; Cytosine; Dioxolanes; Flavonoids; Hematologic Neoplasms; Humans; Immunoconjugates; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Lymphoma, Non-Hodgkin; Multiple Myeloma; NF-kappa B; Nitrogen Mustard Compounds; Oligonucleotides, Antisense; Peptide Hydrolases; Piperidines; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Remission Induction; Rituximab; Staurosporine; Thionucleotides | 2002 |
Fifty years of melphalan use in hematopoietic stem cell transplantation.
Topics: Adenine Nucleotides; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Boronic Acids; Bortezomib; Clofarabine; Graft Survival; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Myeloablative Agonists; Pyrazines; Thalidomide; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous | 2013 |
[Treatment of adult Ph-negative acute lymphoblastic leukemia].
Topics: Adenine Nucleotides; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Boronic Acids; Bortezomib; Clofarabine; Combined Modality Therapy; Consolidation Chemotherapy; Hematopoietic Stem Cell Transplantation; Histocompatibility; HLA Antigens; Humans; Induction Chemotherapy; Maintenance Chemotherapy; Neoplasm, Residual; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrazines; Recurrence; Transplantation Conditioning; Young Adult | 2014 |
1 other study(ies) available for clofarabine and pyrazines
| Article | Year |
|---|---|
Prexasertib, a Chk1/Chk2 inhibitor, increases the effectiveness of conventional therapy in B-/T- cell progenitor acute lymphoblastic leukemia.
Topics: Adenine Nucleotides; Antineoplastic Agents; Apoptosis; Arabinonucleosides; Cell Cycle; Cell Line, Tumor; Cell Survival; Checkpoint Kinase 1; Checkpoint Kinase 2; Clofarabine; Dasatinib; Drug Synergism; Humans; Imatinib Mesylate; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrazines; Pyrazoles | 2016 |